Use of selective inhibitors of EGFR and/other ErbBs were able to reverse multiple diabetes-induced signaling changes including oxidative stress signaling, inflammatory markers, nitric oxide (NO) synthase (eNOS) activity and NO production in the vasculature (Benter et al., 2015; Kassan et al., 2015). This evidence concerns the gene EGFR and diabetes mellitus.